BeFutur Biotechnologies S.A.

Specialisation in the culture of cells and tissues for therapeutic purposes

BeFutur Biotechnologies is a privately-held Swiss biotech company founded in 1995. The company is developing cell-culture and tissue-engineering techniques for the use in aesthetic medicine, plastic surgery, burning care and cosmetics. Headquatered in Geneva, the company’s laboratory facilities are located in Ecublens, Switzerland, with branch offices in Montreal, Canada and Mougins, France. BeFuture and Artifical Life, a New York based provider of software robot technology, are cooperating in the areas of stem cells research, simulation and analysis of cell growth patterns, regenerative medicine and product and vaccine development.

Carla-Maria Khanjian, CEO & President
Irma Kayser, Vice president, Operations
Marc Baly, Finance Director

Mark Baly, Chairman
Georges Damiano
Laurent Delifer
Pierre Laurin

Philippe Tacchini, Dr.
Alfred Balbul, Dr.
Thomas Knittel, Dr.
Hrayr Shahinian, Dr.

14, chemin des Clochettes
1206 Geneva
Switzerland
Phone: +41-22-800-33-10
Fax: +41-22-800-33-13

BeFutur Biotechnologies focuses on cardiology, dermatology, hepatology, oncology, ophthalmology, orthopaedics and dental surgery. The research is centred on autologous human cells using a serum free medium. With this technology BeFuture produces human 3-dimensional reconstituted tissue models for the in vitro testing of cosmetic and pharmacological products. The dermis model, composed of fibroblasts, collagen and a unique matrix of protein, including angiogenesis and immunological factors, has a life span of over 90 days with a physiological barrier functionality equivalent to the one of humans. It showed a 96% accordance to the in vivo data, concerning irritation, phototoxicity, corrosivity and toxicology. The Cardio Cells division of the company is focussed on the development of micro implants and new technologies supporting the regeneration of muscular cardiac cells a and the angiogenesis of cardiac blood vessels. The company uses totally animal serum free medium in order to exclude any risk of contamination. The Art of Skin division is developing injecable (autologous) products for the treatment of wrinkles and cosmetic products for daily maintainance.